At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.
|Articles|August 18, 2012
Biosimilars: Overview of Legislation, Policy, and Current State of Implementation
Advertisement
Enduring Webcast: Biosimilars: Overview of Legislation, Policy and Current State of Implementation
This webcast was brought to you by Amgen.
The faculty for this webcast:
- Defined therapeutic equivalence for small molecule generics
- Described how biologics differ from small molecule drugs
- Explained how the Biologics Price Control and Innovation Act amends the Public Health Service Act and the key requirements of the US biosimilars pathway
- Discussed the difference between biosimilarity and interchangeability
- Reviewed the US legislation for intellectual property and payment provisions
Length of webcast: 14 minutes
System Requirements
PC-based attendees
Required: Windows® 7, Vista, XP, 2003 Server or 2000
Macintosh®-based attendees
Required: Mac OS® X 10.4.11 (Tiger®) or newer
70575-R1-V1
Advertisement
Related to this article
As CKCC nears its sunset, kidney care leaders urge CMS to preserve a dedicated, nephrologist-led accountable care model for advanced kidney disease.
Legal and clinical experts examined the US medical aid in dying framework, its limits, and ethical debates.
Nearly half of working-age adults were inadequately insured in 2026, and half went without needed care due to cost, a Commonwealth Fund survey found.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
3
Former USAID Health Chief Says Aid Cuts Are Costing Children's Lives
4
It’s the Best of Times and Worst of Times for Cancer Care in Tampa
5